Heart failure hospitalisation or cardiovascular death with empagliflozin in patients with type 2 diabetes and high cardiovascular risk: analysis over time in EMPA-REG OUTCOME

23 May 2016 (08:30 - 18:00)

Organised by:

About the speaker

Doctor David Fitchett

St. Michael's Hospital, Toronto (Canada)

22 More presentations in this session

Presentation thumbnail

Zofenopril combined with xanthine oxidase inhibitors may improve survival in post-myocardial infarction patients as compared to placebo or other ACE-inhibitors

Presentation thumbnail

Long-term effects and sustainability of collaborative disease management in systolic heart failure - the extended interdisciplinary network heart failure study

Professor C. Angermann (Wurzburg, DE)

Presentation thumbnail

An implantable pressure sensor for long-term wireless monitoring of cardiac function -first study in man

Doctor J. Baranowski (Linkoping, SE)

Presentation thumbnail

Long-term safety and efficacy of sodium zirconium cyclosilicate (ZS-9) in the treatment of hyperkalaemia: interim analysis of ZS-005, an open-label phase 3 study

Professor S. Anker (Berlin, DE)

Presentation thumbnail

Characteristics of myocardial deformation parameters and their prognostic impact in patients with hypertrophic cardiomyopathy: a speckle tracking imaging analysis

Doctor S. Charfeddine (Sfax, TN)

Access the full session

Session thumbnail

Clinical Forum - Mon. 23 May 08:30 - Tues. 24 May 12:30

The Event

HEART FAILURE 2016

23 May 2016 08:30 CET

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources